Preferred Label : R-CEOP Regimen;
NCIt synonyms : Cyclophosphamide/Etoposide/Oncovin/Prednisone Plus Rituxan Regimen; CEOP/Rituximab Regimen; CEOP Plus Rituximab Regimen; Cyclophosphamide/Etoposide/Prednisone/Rituximab/Vincristine; Cyclophosphamide-Etoposide-Prednisone-Rituximab-Vincristine; Cyclophosphamide/Etoposide/Prednisone/Rituximab/Vincristine Regimen; Cyclophosphamide-Etoposide-Prednisone-Rituximab-Vincristine Regimen;
NCIt related terms : R-CEOP (Etoposide); R-CEOP (Etoposide) (rituximab-blit); R-CEOP (Etoposide) (rituximab-arrx); R-CEOP (Etoposide) (rituximab-pvvr); R-CEOP (Etoposide) (rituximab-rixi); R-CEOP (Etoposide) (rituximab-rite); R-CEOP (Etoposide) (rituximab-abbs); R-CEOP (Etoposide) (rituximab-rixa);
NCIt definition : A regimen consisting of cyclophosphamide, etoposide, vincristine, prednisone and rituximab
that may be used in the treatment of diffuse large B-cell lymphoma (DLBCL) and post-transplant
lymphoproliferative disorders.;
NCI Metathesaurus CUI : CL1905180;
Codes from synonyms : 16155; 127784; 128412; 127941; 128098; 128255; 128569; 128726;
Origin ID : C191761;
UMLS CUI : C5784714;
Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
